Your browser doesn't support javascript.
loading
New horizons from novel therapies in malignant pleural mesothelioma.
Sayan, Mutlay; Mamidanna, Swati; Fuat Eren, Mehmet; Daliparty, Vasudev; Zoto Mustafayev, Teuta; Nelson, Carl; Ohri, Nisha; Jabbour, Salma K; Guven Mert, Aslihan; Atalar, Banu.
Afiliação
  • Sayan M; Department of Radiation Oncology, Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey, USA. ms2641@cinj.rutgers.edu.
  • Mamidanna S; Department of Radiation Oncology, Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey, USA.
  • Fuat Eren M; Radiation Oncology Clinic, Marmara University Istanbul Pendik Education and Research Hospital, Istanbul, Turkey.
  • Daliparty V; Department of Internal Medicine, Raritan Bay Medical Center, Perth Amboy, New Jersey, USA.
  • Zoto Mustafayev T; Department of Medical Oncology, Mehmet Ali Aydinlar Acibadem University, School of Medicine, Istanbul, Turkey.
  • Nelson C; Department of Radiation Oncology, University of Vermont Medical Center, Burlington, Vermont, USA.
  • Ohri N; Department of Radiation Oncology, Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey, USA.
  • Jabbour SK; Department of Radiation Oncology, Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey, USA.
  • Guven Mert A; Department of Radiation Oncology, Acibadem Maslak Hospital, Istanbul, Turkey.
  • Atalar B; Department of Radiation Oncology, Acibadem Maslak Hospital, Istanbul, Turkey.
Adv Respir Med ; 88(4): 343-351, 2020.
Article em En | MEDLINE | ID: mdl-32869268
Malignant pleural mesothelioma (MPM) is a relatively rare, but highly lethal cancer of the pleural mesothelial cells. Its pathoge-nesis is integrally linked to asbestos exposure. In spite of recent developments providing a more detailed understanding of the pathogenesis, the outcomes continue to be poor. To date, trimodality therapy involving surgery coupled with chemotherapy and/or radiotherapy remains the standard of therapy. The development of resistance of the tumor cells to radiation and several che-motherapeutic agents poses even greater challenges in the management of this cancer. Ionizing radiation damages cancer cell DNA and aids in therapeutic response, but it also activates cell survival signaling pathways that helps the tumor cells to overcome radiation-induced cytotoxicity. A careful evaluation of the biology involved in mesothelioma with an emphasis on the workings of pro-survival signaling pathways might offer some guidance for treatment options. This review focuses on the existing treatment options for MPM, novel treatment approaches based on recent studies combining the use of inhibitors which target different pro-survival pathways, and radiotherapy to optimize treatment.
Assuntos
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Neoplasias Pleurais / Amianto / Mesotelioma Maligno Idioma: En Ano de publicação: 2020 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Neoplasias Pleurais / Amianto / Mesotelioma Maligno Idioma: En Ano de publicação: 2020 Tipo de documento: Article